Why Mounjaro (tirzepatide for T2D) Causes Gallbladder Disease: The Mechanism Explained

What the Mounjaro label says

The prescribing information lists acute gallbladder disease as a warning. In the adult placebo-controlled trials, acute gallbladder disease, counted as cholelithiasis, biliary colic and cholecystectomy, was reported by 0.6% of patients on tirzepatide and 0% on placebo [3]. The label also notes that acute gallbladder events such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and in postmarketing use. Its statement is specific: if cholelithiasis is suspected, gallbladder diagnostic studies and clinical follow-up are indicated [3].

That figure belongs to Mounjaro, which is approved for type 2 diabetes in adults and children 10 and older and for cardiovascular risk reduction in adults with type 2 diabetes at high risk; weight loss is not one of its indications [3].

Candidate one: rapid weight loss

Weight loss on tirzepatide is substantial: in the 40-week SURPASS-2 trial, adults with type 2 diabetes lost more weight on tirzepatide than on semaglutide [5].

Bariatric surgery shows how much gallbladder disease can follow fast, large weight loss. In a prospective study of 105 people having gastric bypass, 81 had a normal gallbladder ultrasound at surgery. By 6 months, gallstones had developed in 36% and sludge in 13%, and the percentages stayed about the same at 12 and 18 months. Forty percent of those who developed stones became symptomatic, and nine had an elective cholecystectomy [1]. Two details complicate a simple weight-loss story: the study found no significant difference in percent weight loss between people who did and did not develop stones, and stones were more common in women and in white participants [1]. The study cannot separate the effects of weight loss from other effects of surgery.

A Lancet review of cholesterol gallstone disease says gallstones form when excess biliary cholesterol crystallizes and precipitates in bile, and it describes an active role for both the gallbladder and the intestine [6].

Candidate two: effects on the gallbladder

A 2024 review of GLP-1-based therapies, including tirzepatide, says they slow gastric emptying, and that their effects on the gallbladder may be beneficial, contributing to lower postprandial triglycerides, while potentially increasing the risk of biliary disease [2]. The gallbladder effect is presented as a plausible contributor to biliary risk, not as a measured cause of stone formation. The Mounjaro label separately states that tirzepatide delays gastric emptying, with the delay largest after the first dose and diminishing over time [3].

What the pooled numbers show

A meta-analysis of nine randomized trials with 9,871 participants (6,828 on tirzepatide, 3,043 controls) found the composite of gallbladder or biliary disease significantly more likely with tirzepatide than with placebo or basal insulin: RR 1.97, 95% CI 1.14 to 3.42 [4]. The same analysis did not find a significant increase for cholelithiasis, cholecystitis or biliary disease considered individually [4].

A meta-analysis of 21 trials and 99,599 patients across eight GLP-1 receptor agonists, tirzepatide included, found gallbladder disorders increased by 26% with these drugs versus controls [7].

Comparisons between drugs are harder to make than they look. The Mounjaro label states that adverse reaction rates from clinical trials of one drug cannot be directly compared with rates from trials of another drug [3]. In a meta-analysis of 13 trials in 26,894 adults with obesity but without diabetes, semaglutide raised gallbladder-related disorders, particularly cholelithiasis, by about 2.6 times (95% CI 1.40 to 4.82), while tirzepatide showed no significant biliary risk in that population [8].